ARVN
Closed
Arvinas Inc
7.63
+0.27 (+3.67%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 7.36
Day's Range: 7.3 - 7.82
Send
sign up or login to leave a comment!
When Written:
27.32
Arvinas Inc. is a biopharmaceutical company that develops targeted protein degradation (TPD) therapies for the treatment of various diseases. The company was founded in 2013 and is headquartered in New Haven, Connecticut, United States.
Arvinas' TPD technology is designed to selectively remove disease-causing proteins from cells by using small molecules called "degraders." These degraders are designed to bind to specific proteins and tag them for degradation by the cell's natural protein disposal system.
The company's lead product candidate, ARV-110, is being developed for the treatment of metastatic castration-resistant prostate cancer. Arvinas also has several other TPD programs in preclinical and clinical development for the treatment of other cancers, neurodegenerative disorders, and other diseases.
Arvinas has partnerships with several pharmaceutical companies, including Pfizer, Genentech, and Bayer, to develop TPD therapies for various indications. The company went public in 2018 and is traded on the NASDAQ under the ticker symbol "ARVN."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Arvinas' TPD technology is designed to selectively remove disease-causing proteins from cells by using small molecules called "degraders." These degraders are designed to bind to specific proteins and tag them for degradation by the cell's natural protein disposal system.
The company's lead product candidate, ARV-110, is being developed for the treatment of metastatic castration-resistant prostate cancer. Arvinas also has several other TPD programs in preclinical and clinical development for the treatment of other cancers, neurodegenerative disorders, and other diseases.
Arvinas has partnerships with several pharmaceutical companies, including Pfizer, Genentech, and Bayer, to develop TPD therapies for various indications. The company went public in 2018 and is traded on the NASDAQ under the ticker symbol "ARVN."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








